Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia

作者：Kendall Diebold, Garrett Bourne, Manuel Espinoza‐Gutarra, Zaid Al‐Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy · 发表于：Leukemia & lymphoma/Leukemia and lymphoma · 年份：2024 · DOI：10.1080/10428194.2024.2373324 · 被引用次数：3 · 研究领域：Acute Myeloid Leukemia Research、Retinoids in leukemia and cellular processes、Acute Lymphoblastic Leukemia research

One of the standards of intensive induction therapy for young patients with acute myeloid leukemia (AML) consists of 7 days of cytarabine and 3 days of either idarubicin 12 mg/m2 (IDA) or daunorubi...